Medicines for Malaria Venture (MMV)

Accueil
Schweiz
Genève, Genève
Medicines for Malaria Venture (MMV)

Appeler Itinéraire Site Web

A leading PDP working to reduce the burden of malaria in disease-endemic countries.

29/10/2026

There’s one thing we all have in common: we all began life in the womb.

Our earliest development depends on the health of the women who carry us. Yet protecting the health of pregnant women remains a challenge, particularly when it comes to diseases like .

Pregnant women have historically been excluded from the clinical research needed to inform their treatment. This exclusion has contributed to critical evidence and treatment gaps in malaria care, particularly during the first trimester of pregnancy.

A new article in The Telegraph explores what happens when malaria strikes during pregnancy and how MMV and the Liverpool School of Tropical Medicine are working to make malaria research more inclusive, generate better evidence to guide treatment and expand the options available to pregnant and breastfeeding women.

Read more: bit.ly/4z8CXay

26/10/2026

“If we wait for the next resistance crisis, it’ll be too late.”

We’ve seen before what happens when drug resistance outpaces innovation. When resistance to chloroquine spread and the medicine failed, there was no alternative ready to take its place and millions died.

The lesson still matters today: the parasite won’t stop adapting, so innovation cannot wait for the next resistance crisis.

In conversation with Devex’s Alan Robbins, MMV CEO Martin Fitchet and Joy Phumaphi, Executive Secretary of the African Leaders Malaria Alliance (ALMA), discuss what staying ahead requires, from developing the next generation of antimalarials to ensuring countries can access them.

Because this isn’t only a race between medicines and the parasite. As Joy emphasizes, sustained investment in malaria is an investment in people, children’s futures and the economic prosperity of African countries.

Take a look at the full segment: bit.ly/4igZlHs

22/10/2026

Progress on gender equality is not inevitable. It has to be sustained.

For the fifth consecutive year, MMV has been recognized as a “Very High Performer” in the Global Health 50/50 2026 Gender & Health Index, the highest rating possible.

The index assesses nearly 200 global health organizations, and MMV received a positive assessment across all eight categories, including workplace gender equality policies, leadership representation and sex-disaggregated data.

Five consecutive years of recognition reflect our ongoing commitment to putting our values into practice: making gender equality and inclusion integral to how we work, and bringing together different perspectives and expertise to strengthen the science and partnerships bringing us closer to a -free future.

Explore the full report, including MMV's scorecard: bit.ly/4itEm5H

21/10/2026

New treatment regimens for relapsing are giving countries opportunities to simplify care and reduce onward transmission. But how can we ensure these innovations reach the people who need them?

Tomorrow, 22 October, join the Australian Centre of Research Excellence in Malaria Elimination for a webinar exploring the implementation of single-dose tafenoquine, including the challenges countries face in introducing new treatments and how to overcome them.

MMV's Dr Caroline Lynch will join a panel of experts from Menzies School of Health Research, World Health Organization and other partners to discuss the path forward and how to make the most of tafenoquine's potential to support elimination.

Register for this free webinar and see you there: bit.ly/4hX3ujQ

20/10/2026

A infection during pregnancy can turn a time of joyful anticipation into one of fear and uncertainty.

For women living in endemic regions, particularly in remote communities where reaching a healthcare facility may already be difficult, that uncertainty can be especially distressing.

Malaria during pregnancy can have serious consequences for both mother and baby. And when evidence is limited, treatment decisions become more difficult for healthcare providers and families alike.

A new knowledge portal from World Health Organization brings together practical resources to support the responsible inclusion of pregnant and breastfeeding women in clinical trials. The portal provides guidance and tools to help researchers generate the evidence needed for more informed treatment decisions.

Explore the portal and learn how it can help close longstanding evidence gaps in clinical research involving pregnant and breastfeeding women: bit.ly/3Wayd5E

16/10/2026

Live from the MMV Latin America Regional Meeting, where national malaria programmes, researchers and partners have convened to explore how we can sustain progress towards elimination across Latam.

This meeting is an opportunity to share progress and experiences, explore emerging and discuss how countries can make the most of the tools available to them.

Together, we’re strengthening the connections between evidence, policy and implementation.

16/10/2026

TIME has named MMV and deepmirror's AI-powered Drug Design for Global Health (dd4gh) platform among its Best Inventions of 2026!

dd4gh responds to two pressing needs central to MMV's work: accelerating the discovery of new medicines for and neglected diseases, and broadening access to the technologies that can help scientists in affected countries lead the development of new treatments.

Co-created with researchers from disease-endemic countries, dd4gh is already putting that ambition into practice. Just months after its launch, the majority of its registered users are from low- and middle-income countries.

Read the press release: bit.ly/4zu143h

14/10/2026

From crisis to resilience. That was the ambition behind this year's World Health Summit in Berlin. But what will it take to get there?

For us, part of the answer lies in how we support global health innovation: building on the partnerships and expertise that have delivered new health tools, while giving countries greater leadership in defining the priorities and solutions that matter to them.

Across three days of discussions with governments, researchers, funders and fellow product development partnerships (PDPs), we've explored how the PDP model can evolve to meet this moment and continue delivering the innovations needed to respond to changing global health needs.

As we leave Berlin, let's keep building on this momentum, finding new ways to work together and making the most of the expertise, ideas and capabilities we already have.

A big thank you to everyone who joined us at , engaged in the exchanges we helped facilitate and invited us to contribute to their discussions.

12/10/2026

At a time of profound change for global health, the path forward will depend on our ability to work differently – across sectors, geographies and institutions – and turn shared ambition into collective action.

On the sidelines of the World Health Summit in Berlin, Drugs for Neglected Diseases initiative (DNDi), Global Antibiotic R&D Partnership (GARDP) and MMV convened partners for an open and forward-looking discussion on how collaboration can help sustain health innovation, strengthen local capabilities, and accelerate access to the treatments people need.

The evening reinforced a clear message: progress will require stronger partnerships, bold choices, and long-term commitment. Together, we must create the conditions for needs-driven research and development, mobilize new sources of financing, and ensure that equity and access are built into innovation from the outset.

Our sincere thanks to all our guests for joining us and contributing their perspectives, experience, and ideas. We are especially grateful to our speakers for setting the tone for such a thoughtful and energizing exchange.

The conversations must now translate into deeper cooperation and practical action for a healthier, more equitable and resilient future.

12/10/2026

Global health is evolving, and so are we.

Today, Drugs for Neglected Diseases initiative (DNDi), Medicines Development for Global Health, MMV and TB Alliance published a joint paper on how research, innovation and product development can help build a more sovereign, resilient and equitable future for health.

Countries are leading on their health priorities. We are working with them to put that leadership at the centre of how new health tools are developed: shifting the centre of gravity towards country and regional ownership, reducing duplication without losing specialization, focusing on people-centred R&D, and evolving to increase efficiency and equity.

Drawing on 27 years of experience and 40 new therapeutics, we are ready to keep building, with countries and partners leading.

Read the paper and join the conversation: bit.ly/4enkZsr

Adresse

20, Route De Pré-Bois
Geneva
1215

Téléphone

+41 22 555 03 00

Site Web

http://www.mmv.org/

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque Medicines for Malaria Venture (MMV) publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.